FAQ: AAV Transduction

Q: Is your ViraDuctin™ AAV Transduction Kit compatible with all cell types?

A: Our ViraDuctin™ AAV Transduction kit works by affecting DNA synthesis, the rate limiting step of viral transduction, and is not cell type or AAV serotype specific. We have not tested it on all cell types; it should work as long as it is not toxic to the cells, although we have not yet seen toxicity with any of the cells we have tested.


Q: Will adding crude lysate directly to cells cause toxicity?

A: AAV purification is recommended for in vivo studies, but is not usually necessary for in vitro infections.  A mock transfection control can be used to determine if the lysate will be toxic to the cells.


Q: How long will it take to detect expression? 

A: GFP expression is typically detectable 48 hours after infection with AAV.  Expression of most genes is expected within 2-7 days after in vitro infection; however protein expression levels may vary based on the protein being expressed, the promoter, and the cell type.


Q: How can I improve transduction efficiency with a high titer virus?

A: If you have confirmed that the virus has a high titer but are still seeing a low transduction efficiency when infecting in conjunction with ViraDuctin™ AAV Transduction Kit, it is likely that not enough virus is added to the cells.  The amount of lysate added to cells will depend on the optimal MOI for that cell line, which can be determined from a literature search or from infection with a GFP control virus.  Increasing the MOI used to infect the target cells is likely to improve infection efficiency.